Furthermore, from a clinical perspective, targeting the PGC1-alpha/Sirt3 pathway may enable the development of innovative therapeutic strategies for the treatment of pulmonary fibrosis, which could help address the critical medical need for pulmonary fibrosis therapy. The gene discussed is SIRT3; the disease is pulmonary fibrosis.